Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1,644,695
-
Total 13F shares
-
19,155,756
-
Share change
-
-112,581
-
Total reported value
-
$95,971,150
-
Price per share
-
$5.01
-
Number of holders
-
32
-
Value change
-
-$622,456
-
Number of buys
-
12
-
Number of sells
-
13
Institutional Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) as of Q3 2022
As of 30 Sep 2022,
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) was held by
32 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,155,756 shares.
The largest 10 holders included
PERCEPTIVE ADVISORS LLC, PURA VIDA INVESTMENTS, LLC, Nantahala Capital Management, LLC, Samsara BioCapital, LLC, VR Adviser, LLC, VANGUARD GROUP INC, Soleus Capital Management, L.P., Ikarian Capital, LLC, GEODE CAPITAL MANAGEMENT, LLC, and Clearline Capital LP.
This page lists
32
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.